Zacks Research Brokers Reduce Earnings Estimates for TMO

Thermo Fisher Scientific Inc. (NYSE:TMO) – Investment analysts at Zacks Research lowered their Q2 2025 EPS estimates for Thermo Fisher Scientific in a research note issued on Tuesday, March 18th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $5.59 for the quarter, down from their prior forecast of $5.60. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.68 EPS, Q2 2026 earnings at $6.47 EPS and Q4 2026 earnings at $6.31 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%.

Several other equities research analysts also recently weighed in on the stock. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Bank of America reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Trading Down 0.1 %

TMO opened at $518.04 on Thursday. Thermo Fisher Scientific has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market cap of $195.44 billion, a P/E ratio of 31.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a fifty day moving average price of $546.15 and a two-hundred day moving average price of $556.26.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently modified their holdings of TMO. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at approximately $26,000. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. Finally, Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.